A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar Therapeutics said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares up by nearly 140%. In the 393-patient global ...

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company announced that its mid-stage ...